Abstract
EGFR mutation status is considered as an important predictor of therapeutic responsiveness in non-small-cell lung carcinoma patients. Recent evidence suggests that antioxidant gene polymorphisms are potential predictors of lung cancer risk. Thus, stratification of EGFR mutation-related phenotypes by antioxidant gene polymorphism status can be an effective approach in terms of improving the prognosis of lung cancer patients. The present study was designed to evaluate the distribution frequency of antioxidant gene polymorphisms in lung adenocarcinoma, as well as its association with hotspot EGFR mutations. The study findings revealed that a statistically significant association exists between EGFR L858R mutation and AG + GG genotypes of SOD rs4880 polymorphism. Furthermore, the subgroup analysis data revealed that compared to AA genotype of SOD rs4880, AG + GG genotypes were significantly associated with advanced cancer stage and distant metastasis. Taken together, these findings can be utilized clinically to predict cancer aggressiveness, metastatic, potential and therapeutic responsiveness of lung cancer patients.
Highlights
Lung cancer is the leading cause of death worldwide
A total of 314 lung adenocarcinoma patients were enrolled for the study
While studying the distribution frequency of antioxidant gene polymorphisms in patients with WT- or Epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma, we found no statistically significant association between different polymorphic genotypes and EGFR mutation status (Table 2)
Summary
Lung cancer is the leading cause of death worldwide. It is a highly invasive and metastatic cancer with very poor prognosis. Epidermal growth factor receptor (EGFR) is a transmembrane protein with a tyrosine kinase domain in the intracellular portion It plays important roles in regulating various physiological functions, including cell proliferation and migration [3]. Activating mutations in EGFR gene are observed frequently in non-small-cell lung carcinoma patients [4], and EGFR gene polymorphisms are associated with the risk of lung cancer [5]. It is well-documented that the most common EGFR mutations including exon 19 deletions and L858R mutations strongly predict the sensitivity of lung cancer patients to tyrosine kinase inhibitor treatments [6]. Studies conducted on erlotinib-treated lung cancer patients with EGFR mutations have shown that a specific polymorphism (181946C > T) in EGFR gene is associated with long-term progression-free and overall survival [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
